RETROSPECTIVE ANALYSIS OF REPORTED CASE OF ADVERSE DRUG REACTION - NEUROLEPTIC MALIGNANT SYNDROME ON THE USE OF HALOPERIDOL
Abstract
This article provides a retrospective analysis of a case of adverse drug reactions to the drug haloperidol - neuroleptic malignant syndrome. A literature review on the issue of neuroleptic malignant syndrome was represented. The factors that led to this syndrome development of a particular patient were evaluated. Detailed clinical and pharmacological value of gene polymorphism CYP 2D6 is discussed. The data on the successful use of a therapy of neuroleptic malignant syndrome with ethylmethylhydroxypyridine malat are presented.
About the Authors
V. V. Arkhipov
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», Ministry of Health of the Russian Federation; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
N. G. Berdnikova
I.M. Sechenov First Moscow State Medical University; State Budgetary Healthcare Institution of Moscow «City Clinical Hospital named after I.V. Davydovsky, Department of Healthcare of Moscow»
Russian Federation
Russian Federation
M. V. Zhuravleva
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», Ministry of Health of the Russian Federation; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
V. G. Kukes
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», Ministry of Health of the Russian Federation; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Волков В.П. Злокачественный нейролептический синдром (обзор современной иностранной литературы) // Психиатрия и психофармакотерапия. 2010. № 6.
2. Волков В.П. К проблеме злокачественного нейролептического синдрома // Независимый психиатрический журнал. 2012. № 2.
3. Волков В.П. Злокачественный нейролептический синдром: диагностика и лечение. Часть II (обзор современной иностранной литературы) // Психиатрия и психофармакотерапия. 2011. № 1.
4. Федорова Н.В., Ветохина Т.Н. Диагностика и лечение нейролептических экстрапирамидных синдромов: Учебно-методическое пособие. М., 2006.
5. Шток В.Н., Левин О.С. Лекарственные экстрапирамидные расстройства // В мире лекарств. 2000. № 2.
6. Яничак Ф.Дж., Дэвис Дж.М., Прескорн Ш.Х., Айд Ф.Дж. мл. Принципы и практика психофармакотерапии. 3-е. М., 1999. 728 с.
7. Ananth J., Parameswaran S., Gunatilake S et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 464-70.
8. Chen Y., Guo J.J., Steinbuch M. et al. Risk of neuroleptic malignant syndrome in patients with bipolar disorder: a retrospective, population-based case-control study. Int J Psychiatry Med 2009; 39 (4): 39-50.
9. Voros V., Osvath P., Fekete S., Tenyi T. Antipsychotics and rhabdomyolysis. Differential diagnosis and clinical significance of elevated serum creatine kinase levels in psychiatric practice. Psychiatr Hung 2009; 24 (3): 175-84.
10. Yacoub A., Kohen I., Caraballo A., Francis A. Rating Scale Neuroleptic Malignant Syndrome. Biol Psychiatry 2004; 55: 89S.
11. Schatzberg A.F., Nemeroff C.B. Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998.
12. Strawn J.R., Keck P.E. Jr, Caroff S.N. Neuroleptic malignant syndrome. Am J Psychiatry. 2007 Jun; 164(6): 870-6.
13. Ouyang Z., Chu L. A case of recurrent neuroleptic malignant syndrome. Shanghai Arch Psychiatry. 2013 Aug; 25(4): 256-8.
14. Su Y.P., Chang C.K., Hayes R.D., Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand. 2014 Jul; 130(1): 52-60.
15. Dixit D., Shrestha P., Adelman M. Neuroleptic malignant syndrome associated with haloperidol use in critical care setting: should haloperidol still be considered the drug of choice for the management of delirium in the critical care setting? BMJ Case Rep. 2013 Jul 12.
16. Shaikh N., Al-Sulaiti G., Nasser A., Rahman M.A. Neuroleptic malignant syndrome and closed head injury: A case report and review. Asian J Neurosurg. 2011 Jul; 6(2): 101-5.
17. Catic A.G. Identification and management of in-hospital drug-induced delirium in older patients. Drugs Aging. 2011 Sep 1; 28(9): 737-48.
18. Zivković M.I., Mihaljević-Peles A., Sagud M. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes. Psychiatr Danub. 2010 Mar; 22(1): 112-6.
19. Zhou S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009; 48(12): 761-804.
20. Samer C.F., Ing Lorenzini K., Rollason V., Applications of CYP450 Testing in the Clinical Setting Mol Diagn Ther. Jun 2013; 17(3): 165-184.
21. Кукес В.Г. Метаболизм лекарственных средств: клинико-фармакологические аспекты. 2004; 1827: 40-47.
22. Чаукина С.В. Клинико-фармакологические аспекты метаболизма лекарственных средств под действием изофермента цитохрома Р450 CYP2D6. Трудный пациент. 2008, март http://t-pacient.ru.
23. Итоги исследования отечественного препарата, антиоксиданта второго поколения этоксидола. Пол редакцией акад. РАН Арчакова А.И. и акад. РАН Кукеса В.Г., Международная ассоциация клинических фармакологов и фармацевтов, 2014, стр. 12.
24. Малин Д.И. Козырев В.Н., Равилов Р.С., Спивак Б. Злокачественный нейролептический синдром: эпидемиология, факторы риска, клиника, диагностика, терапия. www.nedug/ru.
Review
For citations:
Arkhipov V.V., Berdnikova N.G., Zhuravleva M.V., Kukes V.G. RETROSPECTIVE ANALYSIS OF REPORTED CASE OF ADVERSE DRUG REACTION - NEUROLEPTIC MALIGNANT SYNDROME ON THE USE OF HALOPERIDOL. Safety and Risk of Pharmacotherapy. 2015;(2):30-39. (In Russ.)
Views:
1138
Email this article 